Inspire Trust Co. N.A. Has $7.01 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Inspire Trust Co. N.A. grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 11.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 130,000 shares of the biopharmaceutical company’s stock after purchasing an additional 13,000 shares during the period. Bristol Myers Squibb comprises approximately 1.2% of Inspire Trust Co. N.A.’s holdings, making the stock its 22nd biggest holding. Inspire Trust Co. N.A.’s holdings in Bristol Myers Squibb were worth $7,012,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Northwestern Mutual Investment Management Company LLC lifted its position in Bristol Myers Squibb by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 172 shares in the last quarter. ESG Planning DBA Harper Investing lifted its position in Bristol Myers Squibb by 1.3% during the 4th quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after buying an additional 180 shares in the last quarter. Novem Group lifted its position in Bristol Myers Squibb by 2.9% during the 4th quarter. Novem Group now owns 6,402 shares of the biopharmaceutical company’s stock worth $345,000 after buying an additional 183 shares in the last quarter. Dominguez Wealth Management Solutions Inc. lifted its position in Bristol Myers Squibb by 0.8% during the 4th quarter. Dominguez Wealth Management Solutions Inc. now owns 22,404 shares of the biopharmaceutical company’s stock worth $1,208,000 after buying an additional 185 shares in the last quarter. Finally, McLean Asset Management Corp lifted its position in Bristol Myers Squibb by 3.1% during the 4th quarter. McLean Asset Management Corp now owns 6,465 shares of the biopharmaceutical company’s stock worth $369,000 after buying an additional 192 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $56.93 on Friday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The stock has a market cap of $116.26 billion, a PE ratio of 15.99, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The stock has a 50-day moving average of $58.36 and a 200-day moving average of $56.25. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Analysts Set New Price Targets

BMY has been the topic of several research reports. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Sunday, April 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. HSBC upped their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Barclays initiated coverage on shares of Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target on the stock. Finally, Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.